Investment Thesis
Acrivon is a pre-revenue biotech company with a solid balance sheet ($95.5M equity, $34.1M cash) but faces critical runway constraints. Operating cash burn of -$20.5M annually provides only ~1.6 years of liquidity without additional funding or revenue generation. Without visible commercialization milestones or clear clinical pipeline data, the company presents unacceptable execution risk relative to available runway.
Strengths
- Strong balance sheet with $95.5M stockholders' equity
- Excellent liquidity position (8.98x current ratio) with minimal debt burden
- Recently reported financial data (Q1 2026)
Risks
- Zero revenue generation with no clear commercialization timeline
- Annual operating cash burn of -$20.5M limits financial runway to ~1.6 years
- Typical biotech risks: drug development, regulatory approval, market competition unquantified
- Significant negative cash flow with minimal capital expenditure suggests development-stage struggles
Key Metrics to Watch
- Quarterly operating cash flow trend and cash balance depletion rate
- Achievement of clinical milestones and regulatory approvals
- Capital raise announcements and dilution impact on equity holders
Financial Metrics
Revenue
N/A
Net Income
-19.0M
EPS (Diluted)
$-0.49
Free Cash Flow
-20.6M
Total Assets
107.8M
Cash
34.1M
Profitability Ratios
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
ROE
-19.9%
ROA
-17.7%
FCF Margin
N/A
Balance Sheet & Liquidity
Current Ratio
8.98x
Quick Ratio
8.98x
Debt/Equity
0.00x
Debt/Assets
11.4%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T08:29:17.628064 |
Data as of: 2026-03-31 |
Powered by Claude AI